Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Diagnosis, Mimics, and Checklists

At a Glance

Lytico-Bodig has no single blood test or brain scan that confirms it during life. Doctors make a working diagnosis by combining movement, muscle, and thinking symptoms with the person’s history, neurological and cognitive exams, and tests such as MRI or EMG to rule out mimics.

Diagnosing Lytico-Bodig (ALS/PDC) is a complex process. Because there is no single validated antemortem biomarker (blood test or brain scan) that can prove someone has it while they are alive, clinicians make a working clinical diagnosis from the phenotype, history, and examination [1][2].

For a patient or caregiver, this process can feel like a long series of tests. Understanding the tools doctors use can help you advocate for a thorough evaluation.

Distinguishing Lytico-Bodig from its “Mimics”

Because Lytico-Bodig is a clinical spectrum, it often looks like several other neurological diseases. Doctors work to identify features that may help clinicians compare possibilities:

  • Progressive Supranuclear Palsy (PSP): Like the “Bodig” form, PSP causes stiffness and frequent falls. However, PSP typically features a specific problem with vertical eye movements. A PSP-like clinical presentation should prompt careful differential diagnosis [3].
  • Standard Parkinson’s Disease: While both involve stiffness and slow movement, “Bodig” symptoms typically do not respond as well to standard Parkinson’s medications like levodopa [2]. (However, levodopa response is not a reliable diagnostic separator because atypical parkinsonism can sometimes respond).
  • Classic ALS: The “Lytico” form looks almost exactly like standard ALS. While standard ALS can include cognitive or behavioral impairment within the ALS-frontotemporal spectrum, Lytico-Bodig often includes severe parkinson-like stiffness [4][5].
  • Alzheimer’s Disease: Memory loss in Lytico-Bodig can look like Alzheimer’s. However, the early addition of physical movement problems usually points toward the ALS/PDC spectrum, though late Alzheimer’s can also develop gait problems [4][6].

The Role of Technology in Diagnosis

While scans cannot “see” Lytico-Bodig directly, they provide important clues.

  • MRI (Magnetic Resonance Imaging): Doctors use MRI primarily to rule out strokes, tumors, or other causes of dementia [3][7].
  • EMG and Nerve Conduction Studies: If there is muscle weakness or twitching, an EMG (electromyogram) is used to check the health of the motor neurons [8][1].
  • Eye Exams (LRPE): A historical research finding called linear retinal pigment epitheliopathy (LRPE) was associated with people with Lytico-Bodig [9]. However, its diagnostic value and specificity are not established for routine practice, so it is neither necessary nor sufficient for diagnosis [9].

A Checklist for a Complete Evaluation

An exhaustive checklist is not required for every patient, but a thorough diagnostic process should consider:

  1. Detailed History: A full review of time spent in Guam or the Western Pacific, any history of eating traditional foods, and a complete family history [10][4].
  2. Cognitive Testing: Formal “pen and paper” tests to measure memory, judgment, and behavior. These help distinguish this from other types of dementia [11][12].
  3. Physical/Neurological Exam: A check of eye movements, muscle strength, reflexes, and “parkinsonian” symptoms like tremors or stiffness [4][2].
  4. Swallow and Breathing Screen: Selected according to the person’s symptoms, early baseline tests of these functions are vital for safety [13].
  5. Medication Trial: A trial of levodopa is often used to see if movement symptoms improve [2].
  6. Genetic Counseling: Depending on family history, a doctor may recommend genetic counseling before any testing [14][3].

The Role of Neuropathology

Clinicians make a working diagnosis from history and testing; definitive neuropathologic confirmation is only possible through postmortem examination of the brain tissue (autopsy), which looks for tau and TDP-43 [6][15]. This is optional and not required for care, but many families find peace in having a definitive answer and contribute to research through brain donation programs [5].

Common questions in this guide

How is Lytico-Bodig diagnosed if there is no single test?
Doctors make a working diagnosis from the pattern of movement, muscle, and thinking changes, the person’s history, and a neurological examination. Cognitive testing, MRI, EMG when needed, and other studies help rule out conditions that can look similar, but no validated blood test or brain scan confirms Lytico-Bodig during life.
What conditions can look like Parkinson-dementia complex of Guam?
Doctors may compare it with progressive supranuclear palsy, typical Parkinson’s disease, classic ALS, and Alzheimer’s disease. Eye-movement findings, the order of movement and memory changes, muscle weakness or twitching, and medication response can provide clues, but no single clue proves the diagnosis.
Can an MRI or EMG confirm Lytico-Bodig?
Not by itself. MRI is mainly used to look for strokes, tumors, or other causes of dementia, while EMG and nerve-conduction studies assess motor-nerve function when weakness or twitching is present. These tests support the evaluation but do not directly show Lytico-Bodig.
Does levodopa response distinguish Lytico-Bodig from Parkinson’s disease?
A levodopa trial may show whether movement symptoms improve, but the result is not a reliable separator on its own. Some people with atypical parkinsonism can respond, so doctors interpret the response alongside the examination and the rest of the history.
Is a retinal pigment epitheliopathy eye finding required for diagnosis?
Linear retinal pigment epitheliopathy, or LRPE, was a historical research finding associated with Lytico-Bodig. Its accuracy and specificity are not established for routine care, so it is neither required nor sufficient to make the diagnosis.
Is a brain autopsy needed to care for someone with Lytico-Bodig?
Definitive confirmation of the characteristic brain changes can only be made by examining brain tissue after death. An autopsy is optional and is not required for care, although some families choose brain donation to seek answers or support research.

Get notified when new evidence is published on Parkinson-dementia complex of Guam.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    [Parkinson-dementia and amyotrophic lateral sclerosis association (complex of Guam). Diagnostic challenge, Mexican patient].

    Aguilar-Vázquez CA, Gallardo-González LI, Raymundo-Carrillo AD, et al.

    Revista medica del Instituto Mexicano del Seguro Social 2023; (61(5)):677-684 doi:10.5281/zenodo.8316479.

    PMID: 37773166
  2. 2

    Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.

    Quinn C, Elman L

    Continuum (Minneapolis, Minn.) 2020; (26(5)):1323-1347 doi:10.1212/CON.0000000000000911.

    PMID: 33003004
  3. 3

    'Hummingbird' Sign in a Patient with Guam Parkinsonism-Dementia Complex.

    Yeo T, Tan LC

    Journal of movement disorders 2017; (10(3)):145-148 doi:10.14802/jmd.17025.

    PMID: 28782342
  4. 4

    Lytico-bodig in Guam: Historical links between diet and illness during and after Spanish colonization.

    Giménez-Roldán S, Steele JC, Palmer VS, Spencer PS

    Journal of the history of the neurosciences 2021; (30(4)):335-374 doi:10.1080/0964704X.2021.1885946.

    PMID: 34197260
  5. 5

    Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC.

    Spencer PS

    Journal of the neurological sciences 2022; (433()):120021 doi:10.1016/j.jns.2021.120021.

    PMID: 34635325
  6. 6

    Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam.

    Verheijen BM, Oyanagi K, van Leeuwen FW

    Frontiers in neurology 2018; (9()):173 doi:10.3389/fneur.2018.00173.

    PMID: 29615966
  7. 7

    Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study.

    Calvo A, Chiò A, Pagani M, et al.

    Journal of neurology 2019; (266(7)):1633-1642 doi:10.1007/s00415-019-09305-0.

    PMID: 30949819
  8. 8

    Brait-Fahn-Schwartz Disease: A Unique Co-Occurrence of Parkinson's Disease and Amyotrophic Lateral Sclerosis.

    Aslam A, Sarmad E, Nawaz A, et al.

    Case reports in neurology 2023; (15(1)):207-214 doi:10.1159/000532092.

    PMID: 37901127
  9. 9

    A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.

    Steele JC, Wresch R, Hanlon SD, et al.

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(9)):1271-5 doi:10.1002/mds.26264.

    PMID: 26153661
  10. 10

    Brain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin.

    Spencer PS, Berntsson SG, Buguet A, et al.

    Journal of the neurological sciences 2025; (468()):123340 doi:10.1016/j.jns.2024.123340.

    PMID: 39667295
  11. 11

    Clinical usefulness of scales for evaluating cognitive impairment in patients with amyotrophic lateral sclerosis.

    Nagashima K, Makioka K, Fujita Y, et al.

    Journal of the neurological sciences 2019; (405()):116414 doi:10.1016/j.jns.2019.07.032.

    PMID: 31419623
  12. 12

    Amyotrophic lateral sclerosis: a clinical review.

    Masrori P, Van Damme P

    European journal of neurology 2020; (27(10)):1918-1929 doi:10.1111/ene.14393.

    PMID: 32526057
  13. 13

    Providing life-sustaining treatments at home for those with Motor Neurone Disease: A qualitative study of bereaved family members' experiences of responsibility.

    Wilson E, Palmer J, Kaltsakas G, et al.

    Palliative medicine 2025; (39(5)):584-593 doi:10.1177/02692163251327866.

    PMID: 40119769
  14. 14

    Defining neurodegeneration on Guam by targeted genomic sequencing.

    Steele JC, Guella I, Szu-Tu C, et al.

    Annals of neurology 2015; (77(3)):458-68 doi:10.1002/ana.24346.

    PMID: 25558820
  15. 15

    Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.

    Condello C, Ayers JI, Dalgard CL, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2023; (120(13)):e2220984120 doi:10.1073/pnas.2220984120.

    PMID: 36952379

This page explains how clinicians evaluate suspected Lytico-Bodig and compare it with similar neurological conditions for informational purposes only; it does not constitute medical advice. A neurologist should interpret your loved one’s symptoms and test results.